| Aducanumab |
0 |
1 |
| Cerebrovascular Accident |
0 |
0.47 |
| Mild Cognitive Impairment |
0 |
0.45 |
| Positron Emission Tomography |
0 |
0.36 |
| Magnetic Resonance Imaging |
0 |
0.35 |
| Squamous Cell Carcinoma |
0 |
0.24 |
| Brain |
0 |
0.8 |
| Cancer |
0 |
0.23 |
| Dementia |
0 |
0.75 |
| Food and Drug Administration (FDA) |
0 |
0.95 |
| Care and Maintenance of Vision |
0 |
0.2 |
| Cataract |
0 |
0.2 |
| Cerebrospinal Fluid |
0 |
0.2 |
| Patient Safety |
0 |
0.2 |
| Cognitive Impairment |
0 |
0.16 |
| A-Scan Biometry |
0 |
0.12 |
| Adverse Effects |
0 |
0.12 |
| Anticoagulation Therapy |
0 |
0.12 |
| Arizona |
0 |
0.12 |
| Caregiver |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Cognition |
0 |
0.12 |
| Geriatrics |
0 |
0.6 |
| Impairment |
0 |
0.12 |
| Organ Failure |
0 |
0.12 |
| Scan |
0 |
0.12 |
| Translational Research |
0 |
0.12 |